Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 18, 2021

View Archived Issues

FDA accepts IND application for StroMel in osteoarthritis of knee

Ultra-low dose infection yields more accurate mouse model of tuberculosis

FDA approves IND for Signature Cord Prime in symptomatic knee osteoarthritis

A regulator of ER proteostasis shows promising antiviral activity against dengue and Zika viruses

New HSP90-CDC37 protein-protein interaction inhibitors with antitumor in vitro and in vivo efficacy

IMU-838 shows some evidence of clinical activity in CALVID-1 study in moderate COVID-19

Nektar announces new collaborations for registrational study of bempegaldesleukin in SCCHN

Topline data from phase Ib study of AMG-0103 in chronic discogenic low back pain

New ENPP2 inhibitors identified at Boehringer Ingelheim

AstraZeneca discovers arginase-1 and arginase-2 inhibitors

University of Texas, Axxam patent CX3CR1 and/or CX3CL1 agonists

Sichuan Haisco Pharmaceutical identifies kappa-opioid receptor agonist derivatives

New anoctamin-1 potentiators synthesized at Enterprise Therapeutics

First patient dosed in phase I study of IkT-148009

Highly phosphorylated GCase M-011 exhibits improved potential in Gaucher disease

N-803 plus BCG shows promise for treating NMIBC

First patient dosed in U.S. phase II/III COVID-19 outpatient study of RHB-107

AbFero receives funding for development of SP-420 for Parkinson's disease

Study may yield ways to harness bacterial antibiotic production

SciSparc signs agreement for phase IIa trial of SCI-110 for Alzheimer agitation

vTv initiates phase I study of PDE4 inhibitor HPP-737 for psoriasis

ABO-102 demonstrates evidence of clinical benefit in patients with MPS IIIA

U.K. clearance for first-in-human study of Avacta's FAP-activated doxorubicin prodrug AVA-6000

GSK initiates phase III program with RSV vaccine candidate GSK-3844766A for older adults

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2024.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for December 24, 2024.
Enhanced Cognition: Lewy body dementia phase II pumps stock
BioWorld
Investors will get more details during the International Lewy Body Dementia Conference in Amsterdam late next month, but Wall Street is already buzzing about...
Experimental mRNA gene therapy suppresses preeclampsia in mice
BioWorld MedTech
A gene therapy based on an enhanced lipid nanoparticle (LNP) loaded with vascular endothelial growth factor (VEGF) mRNA could be developed for the treatment of...
Drug duo to Repare lack in gyno cancers? Phase I shows promise
BioWorld
Wall Street wasn’t jumping up and down about Repare Therapeutics Inc.’s early data in gynecological cancers, though the findings look positive and the company has...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.